We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

User:Ivan E. Wang/Sandbox 1

From Proteopedia

< User:Ivan E. Wang(Difference between revisions)
Jump to: navigation, search
Current revision (16:59, 14 April 2020) (edit) (undo)
 
(30 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase) complex with (''R''/''S'')-emixustat and palmitate'''
+
[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER] width="576" height="324"]
 +
[[/Media:RPE65_with_emixustat.mp4]]
-
<StructureSection load='4rsc' load='4rry' size='340' side='right' caption='Emixustat bound in the active site of RPE65' scene=''>
 
-
Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of ''all-trans''-retinyl ester to ''11-cis''-retinol in the visual cycle.
 
-
(PLACEHOLDER This is a default text for your page '''Ivan E. Wang/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+
[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER]]
-
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.)
+
-
[[Image:BAZ1A_and_BAZ1B_PHD_Sequence_Alignment.PNG|thumb|right|alt=Sequence alignment of BAZ1A and BAZ1B PHD finger motifs|Caption <ref name="do:regular"/>]]
 
-
= Function =
+
[[Media:RPE65_with_emixustat.mp4]]
-
== Structural Features of RPE65 ==
+
-
 
+
-
 
+
-
== Enzymatic Catalyzed Reaction ==
+
-
 
+
-
 
+
-
= Protein-Ligand Interaction =
+
-
== Endogenous Ligand ==
+
-
 
+
-
== Exogenous Ligand ==
+
-
=== (''R'')-Emixustat (ACU-4429) ===
+
-
 
+
-
(''R'')-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E.
+
-
 
+
-
In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (''R'')-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema.
+
-
 
+
-
 
+
-
 
+
-
=== (''S'')-Emixustat ===
+
-
 
+
-
 
+
-
== ''R/S'' Enantiomers Differences ==
+
-
 
+
-
= Disease Implications =
+
-
 
+
-
= Medical Relevance =
+
-
 
+
-
 
+
-
 
+
-
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
+
-
 
+
-
</StructureSection>
+
-
= References =
+
-
<references/>
+

Current revision

[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER] width="576" height="324"] /Media:RPE65_with_emixustat.mp4


PLACEHOLDER


Media:RPE65_with_emixustat.mp4

Proteopedia Page Contributors and Editors (what is this?)

Ivan E. Wang

Retrieved from "http://52.214.119.220/wiki/index.php/User:Ivan_E._Wang/Sandbox_1"
Personal tools